Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, ...
Novo Nordisk NVO shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence. In early September, Novo ...
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...
Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...
Zacks Investment Research on MSN
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...
Novo Nordisk NOVO.B-1.06%decrease; red down pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback